SIC
TARS icon

Salem Investment Counselors’s Tarsus Pharmaceuticals TARS Stock Holding History

Salem Investment Counselors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$10.9K – 1204
2024
Q1 		$10.9K Hold
300
– – ﹤0.01% 818
2023
Q4 		$6.08K Hold
300
– – ﹤0.01% 882
2023
Q3 		$5.33K Buy
+300
New +$5.31K ﹤0.01% 887

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Salem Investment Counselors's TARS Position: Q2 2024 in Review

Salem Investment Counselors sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 300 shares — an estimated $10.9K sold.

Salem Investment Counselors first reported a position in TARS in Q3 2023 and held it in 3 quarters. The position peaked at $10.9K in Q1 2024. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

  • Salem Investment Counselors reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Salem Investment Counselors sold 300 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $10.9K.
  • Salem Investment Counselors first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Salem Investment Counselors's Tarsus Pharmaceuticals position peaked at $10.9K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Salem Investment Counselors's 13F filing for Q2 2024, filed 11 Jul 2024.